loading page

Mechanism of drug resistance to first-line chemotherapeutics mediated by TXNDC17 in neuroblastomas
  • +7
  • Chenggong Zeng,
  • Zhuoran Li,
  • Zhiqing Wei,
  • Tingting Chen,
  • Juan Wang,
  • Junting Huang,
  • Feifei Sun,
  • Jia Zhu,
  • Suying Lu,
  • Zijun Zhen
Chenggong Zeng
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Zhuoran Li
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Zhiqing Wei
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Tingting Chen
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Juan Wang
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Junting Huang
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Feifei Sun
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Jia Zhu
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Suying Lu
Sun Yat-sen University State Key Laboratory of Oncology in South China
Author Profile
Zijun Zhen
Sun Yat-sen University State Key Laboratory of Oncology in South China

Corresponding Author:[email protected]

Author Profile

Abstract

The prognosis of high-risk neuroblastomas (NB) that are resistant to first-line induction chemotherapy is relatively poor. This study explored the mechanism of resistance to first-line chemotherapeutics mediated by TXNDC17 and its potential solutions in NB. The genetic and clinical data of patients with NB were obtained from the Therapeutically Applicable Research to Generate Effective Treatments dataset. TXNDC17 and BECN1 expressions in NB cells were up- and downregulated by transfection with plasmids and shRNA, respectively. Autophagy-related proteins were detected by western blot. Cell viability was determined using cell proliferation and toxicity experiments. Apoptotic cells were detected using flow cytometry. Overall, 1076 pediatric and adolescent patients with NB were enrolled in this study. The 10-year overall survival (OS) rates and event-free survival (EFS) rates for the patients with mutation of BECN1 were 37.4% ± 9.1% and 34.5% ± 8.8%, respectively. For patients with mutation of TXNDC17, the 10-year OS and EFS were 41.4% ± 5.9% and 24.3% ± 5.1%, respectively, which were significantly lower than those in the unaltered group. The overexpression of BECN1 and TXNDC17 reduced NB sensitivity to cisplatin (DDP), etoposide (VP16), and cyclophosphamide (CTX). Autophagy mediated by BECN1 was regulated by TXNDC17, and this process was involved in the resistance to DDP, VP16, and CTX in NB. Suberoylanilide hydroxamic acid (SAHA) can enhance the sensitivity of NB cells to chemotherapeutics by inhibiting TXNDC17, ultimately decreasing autophagy-mediated chemoresistance. Acquired resistance to first-line chemotherapeutics was associated with autophagy mediated by BECN1 and regulated by TXNDC17, which can be reversed by SAHA.
08 Mar 2024Submitted to Cancer Reports
13 Mar 2024Submission Checks Completed
13 Mar 2024Assigned to Editor
27 May 2024Review(s) Completed, Editorial Evaluation Pending
18 Jun 2024Submission Checks Completed
18 Jun 2024Assigned to Editor
19 Aug 2024Review(s) Completed, Editorial Evaluation Pending
19 Sep 2024Editorial Decision: Accept